In this narrative review, the data from key clinical trials incorporating neoadjuvant, adjuvant, and perioperative immunotherapy strategies that have shaped the current treatment landscape in early-stage NSCLC without actionable EGFR and ALK alterations are described and are summarized in Table 1. This evidence concerns the gene ALK and non-small cell lung carcinoma.